company background image
MDXG

MiMedx Group NasdaqCM:MDXG Stock Report

Last Price

US$3.83

Market Cap

US$430.8m

7D

12.3%

1Y

-66.0%

Updated

26 Jun, 2022

Data

Company Financials +
MDXG fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

MDXG Stock Overview

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.

MiMedx Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MiMedx Group
Historical stock prices
Current Share PriceUS$3.83
52 Week HighUS$15.99
52 Week LowUS$3.04
Beta1.92
1 Month Change0%
3 Month Change-17.99%
1 Year Change-65.99%
3 Year Change-5.43%
5 Year Change-74.41%
Change since IPO-24.90%

Recent News & Updates

Shareholder Returns

MDXGUS BiotechsUS Market
7D12.3%10.3%6.6%
1Y-66.0%-24.3%-18.4%

Return vs Industry: MDXG underperformed the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: MDXG underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is MDXG's price volatile compared to industry and market?
MDXG volatility
MDXG Average Weekly Movement11.0%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: MDXG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: MDXG's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a811Tim Wrighthttps://www.mimedx.com

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.

MiMedx Group Fundamentals Summary

How do MiMedx Group's earnings and revenue compare to its market cap?
MDXG fundamental statistics
Market CapUS$430.85m
Earnings (TTM)-US$18.65m
Revenue (TTM)US$257.54m

1.7x

P/S Ratio

-23.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MDXG income statement (TTM)
RevenueUS$257.54m
Cost of RevenueUS$43.58m
Gross ProfitUS$213.96m
Other ExpensesUS$232.61m
Earnings-US$18.65m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.17
Gross Margin83.08%
Net Profit Margin-7.24%
Debt/Equity Ratio56.7%

How did MDXG perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MDXG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MDXG?

Other financial metrics that can be useful for relative valuation.

MDXG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.9x
Enterprise Value/EBITDA-192x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MDXG's PS Ratio compare to its peers?

MDXG PS Ratio vs Peers
The above table shows the PS ratio for MDXG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average19.9x
TNGX Tango Therapeutics
11.2x43.3%US$407.0m
PRE Prenetics Global
1.5x17.3%US$466.1m
INBX Inhibrx
62.9x73.5%US$457.5m
HRTX Heron Therapeutics
3.9x33.2%US$348.4m
MDXG MiMedx Group
1.7x13.4%US$430.8m

Price-To-Sales vs Peers: MDXG is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (19.9x).


Price to Earnings Ratio vs Industry

How does MDXG's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: MDXG is good value based on its Price-To-Sales Ratio (1.7x) compared to the US Biotechs industry average (14.1x)


Price to Sales Ratio vs Fair Ratio

What is MDXG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDXG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.7x
Fair PS Ratio7.4x

Price-To-Sales vs Fair Ratio: MDXG is good value based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (7.4x).


Share Price vs Fair Value

What is the Fair Price of MDXG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MDXG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MDXG's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MDXG's PEG Ratio to determine if it is good value.


Discover undervalued companies

  • Take a look at MiMedx Group's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.

Future Growth

How is MiMedx Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


71.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDXG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: MDXG is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MDXG is expected to become profitable in the next 3 years.

Revenue vs Market: MDXG's revenue (13.4% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: MDXG's revenue (13.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MDXG's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has MiMedx Group performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-48.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MDXG is currently unprofitable.

Growing Profit Margin: MDXG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MDXG is unprofitable, and losses have increased over the past 5 years at a rate of 48.2% per year.

Accelerating Growth: Unable to compare MDXG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDXG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: MDXG has a negative Return on Equity (-14.57%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is MiMedx Group's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MDXG's short term assets ($135.9M) exceed its short term liabilities ($36.6M).

Long Term Liabilities: MDXG's short term assets ($135.9M) exceed its long term liabilities ($52.8M).


Debt to Equity History and Analysis

Debt Level: MDXG has more cash than its total debt.

Reducing Debt: MDXG's debt to equity ratio has increased from 0% to 56.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDXG has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: MDXG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 40.8% each year


Discover healthy companies

Dividend

What is MiMedx Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDXG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDXG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDXG's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MDXG has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Tim Wright (63 yo)

3.08yrs

Tenure

US$4,817,299

Compensation

Mr. Timothy R. Wright, also known as Tim, MBA, has been a Director of MiMedx Group, Inc. since June 17, 2019. He has been the Chief Executive Officer at MiMedx Group, Inc. since joining on May 13, 2019. Mr...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD4.82M) is above average for companies of similar size in the US market ($USD2.83M).

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MDXG's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: MDXG's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MDXG insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.


Top Shareholders

Company Information

MiMedx Group, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: MiMedx Group, Inc.
  • Ticker: MDXG
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$430.845m
  • Shares outstanding: 112.49m
  • Website: https://www.mimedx.com

Number of Employees


Location

  • MiMedx Group, Inc.
  • 1775 West Oak Commons Court, NE
  • Marietta
  • Georgia
  • 30062
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.